Drug treatment as HIV prevention: A research update

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue SUPPL. 1, 2010, Pages

  Metzger, David S ^a   Woody, George E ^a   O'Brien, Charles P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Drug treatment; Drug treatment programs; Prevention; Treatment as HIV prevention

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE PLUS NALOXONE; FLUOXETINE; METHADONE; NALTREXONE;

BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; HEALTH CARE ACCESS; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV EDUCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SEXUAL BEHAVIOR; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; BUPRENORPHINE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; NALTREXONE; RISK REDUCTION BEHAVIOR; SEXUAL BEHAVIOR;

EID: 78449287335     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f9c10b     Document Type: Review

References (79)

1. Masur H, Michelis MA, Greene JB, et al. An outbreak of communityacquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305:1431-1438.
2. Ginzburg HM. Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep. 1984;99:206-212.
3. Mahy M, Warner-Smith M, Stanecki KA, et al. Measuring the impact of the global response to the AIDS epidemic: challenges and future directions. J Acquir Immune Defic Syndr. 2009;52(Suppl 2):S152-S159.
4. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIVAIDS. 2009;4: 240-246.
5. Joint United Nations Program on HIV/AIDS (UNAIDS). AIDS Epidemic Update 09. UNAIDS; November 2009. Geneva, Switzerland: UNAIDS, WHO; November 2009. UNAIDS/09.36E/JC1700E.
6. Bogart LM, Kral AH, Scott A, et al. Condom attitudes and behaviors among injection drug users participating in California syringe exchange programs. AIDS Behav. 2005;9:423-432. (Pubitemid 43207838)
7. Bogart LM, Kral AH, Scott A, et al. Sexual risk among injection drug users recruited from syringe exchange programs in California. Sex Transm Dis. 2005;32:27-34. (Pubitemid 40054158)
8. Bluthenthal RN, Do DP, Finch B, et al. Community characteristics associated with HIV risk among injection drug users in the San Francisco Bay Area: a multilevel analysis. J Urban Health. 2007;84:653-666.
9. Woody GE, VanEtten-Lee ML, McKirnan D, et al. Substance use among men who have sex with men: comparison with a national household survey. J Acquir Immune Defic Syndr. 2001;27:86-90.
10. Chesney MA, Koblin BA, Barresi PJ, et al. An individually tailored intervention for HIV prevention: baseline data from the EXPLORE study. Am J Public Health. 2003;93:933-938.
11. Menza TW, Hughes JP, Celum CL, et al. Prediction of HIV acquisition among men who have sex with men. Sex Transmit Dis. 2009;36:547-555.
12. Koblin B, Chesney M, Coates T, et al. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet. 2004;364:41-50.
13. Koblin BA, Husnik MJ, Colfax G, et al. Risk factors for HIV infection among men who have sex with men. AIDS. 2006;20:731-739.
14. Lawrinson P, Ali R, Buavirat A, et al. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS. Addiction. 2008;103:1484-1492.
15. Haverkos HW. HIV/AIDS and drug abuse: epidemiology and prevention. J Addict Dis. 1998;17:91-103.
16. Allison M, Hubbard RL. Drug-abuse treatment process-a review of the literature. Int J Addict. 1985;20:1321-1345.
17. Ball JC, Lange WR, Myers CP, et al. Reducing the risk of aids through methadone-maintenance treatment. J Health Soc Behav. 1988;29:214-226.
18. Gowing LR, Farrell M, Bornemann R, et al. Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med. 2006;21:193-195.
19. Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx, New York City. Public Health Rep. 1998;113(Suppl)1:107-115.
20. Qian HZ, Hao C, Ruan YH, et al. Impact of methadone on drug use and risky sex in China. J Subst Abuse Treat. 2008;34:391-397.
21. Caplehorn JRM, RossMW. Methadone-maintenance and the likelihood of risky needle-sharing. Int J Addict. 1995;30:685-698.
22. Metzger DS, Woody GE, McLellan AT, et al. Human-immunodeficiencyvirus seroconversion among intravenous-drug-users in-of-treatment and out-of-treatment-an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-1056.
23. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance-abuse treatment. JAMA. 1993;269:1953-1959.
24. Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry. 1999;156:27-33.
25. Avants SK, Margolin A, Usubiaga MH, et al. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. J Subst Abuse Treat. 2004;26:67-78.
26. Wong KH, Lee SS, Lim WL, et al. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat. 2003;24:233-239.
27. Hubbard RL, Craddock SG, Flynn PM, et al. Overview of 1-year followup outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav. 1997;11:261-278.
28. Booth RE, Crowley TJ, Zhang YM. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 1996;42:11-20.
29. Gossop M, Marsden J, Stewart D, et al. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV. 2002;14:77-93. (Pubitemid 34095168)
30. Gottheil E, Lundy A, Weinstein SP, et al. Does intensive outpatient cocaine treatment reduce AIDS risky behaviors? J Addict Dis. 1998;17: 61-69.
31. Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000;77:331-345.
32. Novick DM, Joseph H, Croxson TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadonemaintenance patients. Arch Intern Med. 1990;150:97-99.
33. Moss AR, Vranizan K, Gorter R, et al. HIV seroconversion in intravenous-drug-users in San-Francisco, 1985-1990. AIDS. 1994;8: 223-231.
34. Serpelloni G, Carrieri MP, Rezza G, et al. Methadone treatment as a determinant of HIV risk reduction among injecting drug-users-a nested case-control study. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV. 1994;6:215-220.
35. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health. 1999;113:97-106.
36. Metzger DS, Navaline H. HIV prevention among injection drug users: the need for integrated models. J of Urban Health. 2003;80:59-66.
37. Metzger DS, Navaline H. Human immunodeficiency virus prevention and the potential of drug abuse treatment. Clin Infect Dis. 2003;37:S451-S456.
38. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17-31.
39. Farrell M, Gowing L, Marsden J, et al. Effectiveness of drug dependence treatment in HIV prevention. Int J Drug Policy. 2005;16:S67-S75.
40. Gowing L, Farrell M, Boremann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008;2:CD004145.
41. Bao YP, Liu ZM. Systematic review of HIV and HCV infection among drug users in China. Int J STD AIDS. 2009;20:399-405.
42. Li J HT, Zhang C, Liu H, et al. The Chinese government's response to drug use and HIV/AIDS: A review of policies and programs. Harm Reduction Journal. 2010;7:4.
43. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374.
44. Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an officebased treatment for opiate dependence. Drug Alcohol Depend. 2003; 70(Suppl):S79-S85.
45. Sullivan LE, Fiellin DA. Buprenorphine: Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41:891-896.
46. Sullivan LE, Metzger DS, Fudala PJ, et al. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150-158.
47. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat. 2008;35:87-92.
48. Meade CS, Weiss RD, Fitzmaurice GM, et al. HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA Clinical Trials Network Multisite Study. J Acquir Immune Defic Synd. 2010;55: 65-72.
49. Schackman BR, Merrill JO, McCarty D, et al. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43:S247-S253.
50. Doran CM, Shanahan M, Mattick RP, et al. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71:295-302.
51. Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371: 2192-2200.
52. Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St Petersburg, Russia. J Subst Abuse Treat. 2006;31:319-328.
53. De Cock KM, Crowley SP, Lo Y-R, et al. Preventing HIV transmission with antiretrovirals. Bull World Health Organ. 2009;87:488-488A.
54. Vermund SH, Hodder SL, Justman JE, et al. Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis. 2010; 50:S149-S155.
55. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis. 2010;50:S85-S95.
56. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198:59-67.
57. Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV. 2009;21:655-663.
58. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010;21:4-9.
59. Uhlmann S, Milloy MJ, Kerr T, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105:907-913.
60. Lucas GM, Mullen BA, Weidle PJ, et al. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis. 2006;42:1628-1635.
61. Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412-420.
62. Roux P, Carrieri MP, Villes V, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008;103:1828-1836.
63. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIVinfected injection drug users receiving antiretroviral treatment. Clin Infect Dis. 2009;49:1433-1440.
64. Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262-270.
65. Tross S, Hanner J, Hu M-C, et al. Substance use and high risk sexual behaviors among women in psychosocial outpatient and methadone maintenance treatment programs. Am J Drug Alcohol Abuse. 2009;35: 368-374.
66. Rudy ET, Shoptaw S, Lazzar M, et al. Methamphetamine use and other club drug use differ in relation to HIV status and risk behavior among gay and bisexual men. Sex Transmit Dis. 2009;36:693-695.
67. Meader N, Li R, Des Jarlais DC, et al. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev. 2010;1:CD007192.
68. Tross S, Campbell ANC, Cohen LR, et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA clinical trials network trial. J Acquir Immune Defic Syndr. 2008;48:581-589.
69. Calsyn DA, Hatch-Maillette M, Tross S, et al. Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. J Subst Abuse Treat. 2009;37:138-150.
70. Calsyn DA, Crits-Christoph P, Hatch-Maillette MA, et al. Reducing sex under the influence of drugs or alcohol for patients in substance abuse treatment. Addiction. 2010;105:100-108.
71. Shoptaw S, Reback CJ, Peck JA, et al. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78: 125-134.
72. Shoptaw S, Reback CJ, Larkins S, et al. Outcomes using two tailored behavioral treatments for substance abuse in urban gay and bisexual men. J Subst Abuse Treat. 2008;35:285-293.
73. Centers for Disease Control and Prevention. HIV infection among injection-drug users-34 states, 2004-2007. MMWR Morb Mortal Wkly Rep. 2009;58:1291-1295.
74. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
75. Pollack HA, D'Aunno T, Lamar B. Outpatient substance abuse treatment and HIVprevention: an update. J Subst Abuse Treat. 2006;30:39-47.
76. Knudsen HK, Oser CB. Availability of HIV-related health services in adolescent substance abuse treatment programs. AIDS Care-Psychological and Socio-Medical Aspects of AIDS/HIV. 2009;21:1238-1246.
77. Sorensen JL, Haug NA, Delucchi KL, et al. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007;88:54-63.
78. Barnett PG, Sorensen JL, Wong W, et al. Effect of incentives for medication adherence on health care use and costs in methadone patients with HIV. Drug Alcohol Depend. 2009;100:115-121.
79. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014-1028.